Myelodysplastic Syndromes and Metabolism
Myelodysplastic syndromes (MDS) are acquired clonal stem cell disorders exhibiting ineffective hematopoiesis, dysplastic cell morphology in the bone marrow, and peripheral cytopenia at early stages; while advanced stages carry a high risk for transformation into acute myeloid leukemia (AML). Genetic...
Main Authors: | Ekaterina Balaian, Manja Wobus, Martin Bornhäuser, Triantafyllos Chavakis, Katja Sockel |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-10-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/20/11250 |
Similar Items
-
P725: METABOLIC PROPERTIES OF MESENCHYMAL STROMAL CELLS IN MYELODYSPLASTIC SYNDROMES
by: E. Balaian, et al.
Published: (2022-06-01) -
Emerging Therapies for the Myelodysplastic Syndromes
by: Jonathan Canaani
Published: (2019-12-01) -
Hematologic malignancies : myelodysplastic syndromes /
by: Deeg, H. Joachim (Hans Joachim), 1945-
Published: (2006) -
EnvIRONmental Aspects in Myelodysplastic Syndrome
by: Verena Petzer, et al.
Published: (2021-05-01) -
From Immune Dysregulations to Therapeutic Perspectives in Myelodysplastic Syndromes: A Review
by: Thibault Comont, et al.
Published: (2021-10-01)